84 results
8-K
EX-99.1
OPGN
Opgen Inc
10 Aug 23
OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update
4:31pm
was approximately $1.65 million, an increase of approximately 15% compared to approximately $1.44 million in the first half of 2022
Signed FIND R&D collaboration … to date, the Company reached the following key milestones:
OpGen subsidiary, Curetis, and FIND signed an extension to their R&D collaboration agreement
8-K
EX-99.1
OPGN
Opgen Inc
15 May 23
OpGen Reports First Quarter 2023 Financial Results and Provides Business Update
5:11pm
subsidiary, Curetis, met all remaining key milestones in its R&D collaboration project with the Foundation for Innovative New Diagnostics (FIND … ).
Signed a short-term expansion of Curetis’ R&D collaboration with FIND. The work already completed under the collaboration was expanded by three work
424B3
e0c 562gu
3 May 23
Prospectus supplement
4:43pm
8-K
EX-99.1
xx00bi
30 Mar 23
OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
5:11pm
8-K
EX-99.2
qkovy0t5ra 1h1sgh5y
30 Mar 23
OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
5:11pm
8-K
EX-99.1
eknuuab lfg
10 Nov 22
OpGen Reports Third Quarter 2022 Financial Results and Provides Business Update
4:19pm
8-K
EX-99.1
7v4wz
20 Sep 22
OpGen Subsidiary Curetis and FIND Sign R&D Collaboration Agreement for Unyvero A30 RQ Platform
4:38pm
8-K
EX-99.1
slf 8o21tggs
11 Aug 22
OpGen Reports Second Quarter 2022 Financial Results and Provides Business Update
5:20pm
8-K
EX-99.1
i6kebnirl
29 Mar 22
OpGen Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
4:16pm
8-K
EX-99.1
xgf9kf93g9 ch8
12 Nov 21
OpGen Reports Third Quarter 2021 Financial Results and Provides Business Update
6:35am